PYC Therapeutics Limited (PYC.AX)
ASX · AUD · Healthcare · Biotechnology
A$1.92 (+9.40%) as of
Key statistics
- Market cap
- 1.89B
- Forward P/E
- -22.93
- EPS (TTM)
- -0.0600
- Dividend yield
- 0.00%
- 52-week range
- 1.0450 – 2.9300
- Beta
- 1.01
- Revenue (TTM)
- 25.99M
- Profit margin
- -166.73%
- Analyst target
- A$4.07
- Volume
- 4.37M
About PYC Therapeutics Limited
PYC Therapeutics Limited, a clinical stage drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. It is developing PYC-003, which is in Phase1a/1b multiple ascending dose study for polycystic kidney disease; PYC-002, a Phelan McDermid Syndrome; PYC-001 for the treatment of Phelan-McDermid Syndrome; PYC-001, which is in Phase 1b multiple ascending dose study for autosomal dominant optic atrophy; and VP-001 for the treatment of retinitis pigmentosa type 11. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Nedlands, WA, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.